Lyme Disease Treatment Market (By Treatment Type: Medication, Tick Removal; By Type of Bacteria: Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia garinii, Others; By Route of Administration: Oral, Injectable, Topical; By Application; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2021-2030

Chapter 1.    Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.    Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.    Executive Summary

3.1.  Market Snapshot

Chapter 4.    Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.     Raw Material Procurement Analysis

4.3.2.     Sales and Distribution Channel Analysis

4.3.3.     Downstream Buyer Analysis

Chapter 5.    Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.     Market Drivers

5.1.2.     Market Restraints

5.1.3.     Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.     Bargaining power of suppliers

5.2.2.     Bargaining power of buyers

5.2.3.     Threat of substitute

5.2.4.     Threat of new entrants

5.2.5.     Degree of competition

Chapter 6.    Competitive Landscape

6.1.1.     Company Market Share/Positioning Analysis

6.1.2.     Key Strategies Adopted by Players

6.1.3.     Vendor Landscape

6.1.3.1.          List of Suppliers

6.1.3.2.          List of Buyers

Chapter 7.    Global Lyme Disease Treatment Market, By Treatment Type

7.1.  Lyme Disease Treatment Market, by Treatment Type, 2021-2030

7.1.1.     Medication

7.1.1.1.          Market Revenue and Forecast (2016-2030)

7.1.2.     Tick Removal

7.1.2.1.          Market Revenue and Forecast (2016-2030)

Chapter 8.    Global Lyme Disease Treatment Market, By Type of Bacteria

8.1.  Lyme Disease Treatment Market, by Type of Bacteria, 2021-2030

8.1.1.     Borrelia burgdorferi

8.1.1.1.          Market Revenue and Forecast (2016-2030)

8.1.2.     Borrelia mayonii

8.1.2.1.          Market Revenue and Forecast (2016-2030)

8.1.3.     Borrelia afzelii

8.1.3.1.          Market Revenue and Forecast (2016-2030)

8.1.4.     Borrelia garinii

8.1.4.1.          Market Revenue and Forecast (2016-2030)

8.1.5.     Others

8.1.5.1.          Market Revenue and Forecast (2016-2030)

Chapter 9.    Global Lyme Disease Treatment Market, By Route of Administration

9.1.  Lyme Disease Treatment Market, by Route of Administration, 2021-2030

9.1.1.     Oral

9.1.1.1.          Market Revenue and Forecast (2016-2030)

9.1.2.     Injectable

9.1.2.1.          Market Revenue and Forecast (2016-2030)

9.1.3.     Topic

9.1.3.1.          Market Revenue and Forecast (2016-2030)

Chapter 10.Global Lyme Disease Treatment Market, By Application

10.1.          Lyme Disease Treatment Market, by Application, 2021-2030

10.1.1.  Humans

10.1.1.1.       Market Revenue and Forecast (2016-2030)

10.1.2.  Animals

10.1.2.1.       Market Revenue and Forecast (2016-2030)

Chapter 11.Global Lyme Disease Treatment Market, By Distribution Channel

11.1.          Lyme Disease Treatment Market, by Distribution Channel, 2021-2030

11.1.1.  Hospital Pharmacies

11.1.1.1.       Market Revenue and Forecast (2016-2030)

11.1.2.  Retail Pharmacies

11.1.2.1.       Market Revenue and Forecast (2016-2030)

11.1.3.  Online Pharmacies

11.1.3.1.       Market Revenue and Forecast (2016-2030)

Chapter 12.Global Lyme Disease Treatment  Market, Regional Estimates and Trend Forecast

12.1.          North America

12.1.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.1.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.1.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.1.4.  Market Revenue and Forecast, by Application (2016-2030)

12.1.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.1.6.  U.S.

12.1.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.1.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.1.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.1.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.1.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.1.7.  Rest of North America

12.1.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.1.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.1.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.1.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.1.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.          Europe

12.2.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.4.  Market Revenue and Forecast, by Application (2016-2030)

12.2.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.6.  UK

12.2.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.7.  Germany

12.2.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.8.  France

12.2.8.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.8.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.8.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.8.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.2.9.  Rest of Europe

12.2.9.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.2.9.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.2.9.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.2.9.4.       Market Revenue and Forecast, by Application (2016-2030)

12.2.9.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.          APAC

12.3.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.4.  Market Revenue and Forecast, by Application (2016-2030)

12.3.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.6.  India

12.3.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.7.  China

12.3.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.8.  Japan

12.3.8.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.8.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.8.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.8.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.3.9.  Rest of APAC

12.3.9.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.3.9.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.3.9.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.3.9.4.       Market Revenue and Forecast, by Application (2016-2030)

12.3.9.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.          MEA

12.4.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.4.  Market Revenue and Forecast, by Application (2016-2030)

12.4.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.6.  GCC

12.4.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.7.  North Africa

12.4.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.8.  South Africa

12.4.8.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.8.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.8.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.8.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.8.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.4.9.  Rest of MEA

12.4.9.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.4.9.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.4.9.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.4.9.4.       Market Revenue and Forecast, by Application (2016-2030)

12.4.9.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.5.          Latin America

12.5.1.  Market Revenue and Forecast, by Treatment Type (2016-2030)

12.5.2.  Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.5.3.  Market Revenue and Forecast, by Route of Administration (2016-2030)

12.5.4.  Market Revenue and Forecast, by Application (2016-2030)

12.5.5.  Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.5.6.  Brazil

12.5.6.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.5.6.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.5.6.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.5.6.4.       Market Revenue and Forecast, by Application (2016-2030)

12.5.6.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

12.5.7.  Rest of LATAM

12.5.7.1.       Market Revenue and Forecast, by Treatment Type (2016-2030)

12.5.7.2.       Market Revenue and Forecast, by Type of Bacteria (2016-2030)

12.5.7.3.       Market Revenue and Forecast, by Route of Administration (2016-2030)

12.5.7.4.       Market Revenue and Forecast, by Application (2016-2030)

12.5.7.5.       Market Revenue and Forecast, by Distribution Channel (2016-2030)

Chapter 13.   Company Profiles

13.1.                 GlaxoSmithKline plc

13.1.1.  Company Overview

13.1.2.  Product Offerings

13.1.3.  Financial Performance

13.1.4.  Recent Initiatives

13.2.                 Pfizer, Inc.

13.2.1.  Company Overview

13.2.2.  Product Offerings

13.2.3.  Financial Performance

13.2.4.  Recent Initiatives

13.3.                 Novartis AG

13.3.1.  Company Overview

13.3.2.  Product Offerings

13.3.3.  Financial Performance

13.3.4.  Recent Initiatives

13.4.                 F. Hoffmann-La Roche Ltd.

13.4.1.  Company Overview

13.4.2.  Product Offerings

13.4.3.  Financial Performance

13.4.4.  Recent Initiatives

13.5.                 Almirall

13.5.1.  Company Overview

13.5.2.  Product Offerings

13.5.3.  Financial Performance

13.5.4.  Recent Initiatives

13.6.                 LLC

13.6.1.  Company Overview

13.6.2.  Product Offerings

13.6.3.  Financial Performance

13.6.4.  Recent Initiatives

13.7.                 Mayne Pharma

13.7.1.  Company Overview

13.7.2.  Product Offerings

13.7.3.  Financial Performance

13.7.4.  Recent Initiatives

13.8.                 Boehringer Ingelheim International GmbH

13.8.1.  Company Overview

13.8.2.  Product Offerings

13.8.3.  Financial Performance

13.8.4.  Recent Initiatives

13.9.                 Galderma Laboratories

13.9.1.  Company Overview

13.9.2.  Product Offerings

13.9.3.  Financial Performance

13.9.4.  Recent Initiatives

13.10.              L.P.

13.10.1.                   Company Overview

13.10.2.                   Product Offerings

13.10.3.                   Financial Performance

13.10.4.                   Recent Initiatives

Chapter 14.   Research Methodology

14.1.                 Primary Research

14.2.                 Secondary Research

14.3.                 Assumptions

Chapter 15.   Appendix

15.1.                 About Us

15.2.                 Glossary of Terms